Arranto A J, Sotaniemi E A
Scand J Gastroenterol. 1981;16(7):865-72. doi: 10.3109/00365528109181815.
Alpha-methyldopa-induced liver injury was studied in six patients by clinical, biochemical, histologic, and morphometric methods. The patients, all women, developed hepatic injury after long-term therapy lasting 2 to 8 years. Withdrawal of the drug resulted in improvement of the symptoms. Hepatitis with fibrosis and moderate to severe fatty accumulation was seen in most of the liver biopsies at onset of symptoms. Follow-up ranged from 7 to 24.5 months, at the end of which the liver function test results were in the normal range. A second liver biopsy showed significant decrease in fatty infiltration. Three patients showed a decrease in lipid content from moderate to mild or normal and two other patients from severe to moderate. A 73-year-old patient had chronic aggressive hepatitis with massive necrosis of the parenchyma after 8 years of therapy, and follow-up biopsy 12 months later showed cirrhosis. In this study alpha-methyldopa withdrawal resulted in a reduction of lipid and fibrous trabeculae content, possibly caused by alpha-methyldopa-induced derangement of liver function.
采用临床、生化、组织学和形态测量学方法对6例α-甲基多巴引起的肝损伤患者进行了研究。这些患者均为女性,在接受了为期2至8年的长期治疗后出现肝损伤。停药后症状有所改善。症状出现时,大多数肝脏活检显示有伴有纤维化以及中度至重度脂肪堆积的肝炎。随访时间为7至24.5个月,随访结束时肝功能检查结果在正常范围内。第二次肝脏活检显示脂肪浸润显著减少。3例患者的脂质含量从中度降至轻度或正常,另外2例患者从重度降至中度。一名73岁的患者在治疗8年后出现慢性侵袭性肝炎,实质出现大片坏死,12个月后的随访活检显示为肝硬化。在本研究中,停用α-甲基多巴导致脂质和纤维小梁含量减少,这可能是由α-甲基多巴引起的肝功能紊乱所致。